4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 1 | 2024-03-27 | 2025-10-31 |
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Terminated | Kimberly Perez, MD | 8 | 2023-01-06 | 2024-12-17 |
| Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT - Pancreatic Cancer, Pancreatic Carcinoma Non-resectable | Phase 2 | Terminated | NewLink Genetics Corporation | 10 | 2015-04-01 | 2020-05-28 |
| Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer gemcitabine/nab-paclitaxel, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer | Phase 2 | Terminated | Nathan Bahary, MD | 2 | 2014-12-01 | 2018-07-26 |
Pancreatic Neoplasms (3) · Neoplasms (1)
BioNTech SE (1) · Kimberly Perez, MD (1) · Nathan Bahary, MD (1) · NewLink Genetics Corporation (1)
United States (4)
2023 (1)